Prothena (NASDAQ: PRTA) counsel details ordinary share and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Prothena Corp Public Ltd Co General Counsel & Company Secretary Michael John Isaacs has reported his initial holdings. He directly owns 48,825 ordinary shares. He also holds several stock options over ordinary shares at exercise prices ranging from $10.99 to $52.97, with expiration dates between 2030 and 2036.
Certain options are already fully vested, while others vest 25% on specific dates and then in equal monthly installments, in each case subject to his continued employment with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Isaacs Michael John
Role
General Counsel & Company Sec.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares, par value $0.01 per share | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,500 shares (Direct, null);
Ordinary Shares, par value $0.01 per share — 48,825 shares (Direct, null)
Footnotes (1)
- The option is fully vested. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on March 2, 2024, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 10, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Key Figures
Direct ordinary shares: 48,825 shares
Option grant 1: 50,000 shares at $10.50
Option grant 2: 37,500 shares at $9.36
+3 more
6 metrics
Direct ordinary shares
48,825 shares
Directly owned ordinary shares reported on Form 3
Option grant 1
50,000 shares at $10.50
Stock option over ordinary shares, expires 2036-04-10
Option grant 2
37,500 shares at $9.36
Stock option over ordinary shares, expires 2036-03-03
Option grant 3
8,612 shares at $14.95
Stock option over ordinary shares, expires 2035-03-05
Option grant 4
12,000 shares at $30.30
Stock option over ordinary shares, expires 2034-02-27
Option grant 5
17,500 shares at $10.99
Stock option over ordinary shares, expires 2030-04-01
Key Terms
Stock Option (Right to Buy), Ordinary Shares, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "10.5000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-04-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"The shares subject to the option vested and became exercisable as to 25%"
FAQ
What does Prothena (PRTA) General Counsel Michael John Isaacs report on this Form 3?
He reports his initial ownership in Prothena, including 48,825 directly held ordinary shares and multiple stock option awards. These options give him the right to buy additional ordinary shares at preset prices before their respective expiration dates.
What are the key stock option positions held by Prothena (PRTA) General Counsel Isaacs?
He holds several stock options, including options over 50,000 ordinary shares at a $10.50 exercise price expiring in 2036, and 37,500 shares at $9.36 expiring in 2036, plus additional grants with higher exercise prices and earlier expiration dates.
How do Michael John Isaacs’s Prothena (PRTA) stock options vest over time?
Some options are fully vested, while others vest 25% on specific initial vesting dates and then in 1/48th monthly installments. Each vesting schedule is conditioned on his continued employment with Prothena on the relevant vesting dates.